Pancreatic Cancer Research

ResearcherProvidence Portland Medical CenterActive in the last 2 years

Michael James Gough

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5575-0074; OpenAlex author ID A5051320936; NIH RePORTER profile ID 10127825. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
1
Labs led
1
Collaborators
25
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper, 1 grant · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.03.004↗
  2. Myeloid MyD88 restricts CD8+ T cell response to radiation therapy in pancreatic cancer. Last author DOI 10.1038/s41598-023-35834-w↗
  3. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Co-author DOI 10.1007/s00262-020-02701-w↗
  4. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Co-author DOI 10.1080/2162402x.2021.1900635↗
  5. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  6. Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. Last author DOI 10.1371/journal.pone.0238380↗
  7. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0211117↗
  8. Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2018.1757↗
  9. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pa… Co-author DOI 10.1186/s40425-016-0149-6↗

Grants 1

  1. High dose radiation therapy to direct immune responses to pancreatic cancer R01CA182311↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kristina Hoot Young · 5 shared papers, 2016–2026 · strength 0.59
  2. Andrew J. Gunderson · 4 shared papers, 2019–2026 · strength 0.54
  3. Marka R. Crittenden · 5 shared papers, 2016–2023 · strength 0.53
  4. Terry R. Medler · 3 shared papers, 2020–2023 · strength 0.40
  5. Paul Hansen · 4 shared papers, 2016–2021 · strength 0.33
  6. Ephraim Shin-Tian Tang · 3 shared papers, 2018–2021 · strength 0.28
  7. Elijah Kirschstein · 1 shared paper, 2026 · strength 0.26
  8. Brady M. Bernard · 2 shared papers, 2020–2021 · strength 0.19
  9. Karyn A. Goodman · 2 shared papers, 2021 · strength 0.19
  10. Miles Piper · 2 shared papers, 2021 · strength 0.19
  11. Ayman J. Oweida · 2 shared papers, 2021 · strength 0.19
  12. Sana D. Karam · 2 shared papers, 2021 · strength 0.19
  13. Adam Christopher Mueller · 2 shared papers, 2021 · strength 0.19
  14. Marco Del Chiaro · 2 shared papers, 2021 · strength 0.19
  15. Richard David Schulick · 2 shared papers, 2021 · strength 0.19
  16. Kirk Charles Hansen · 2 shared papers, 2021 · strength 0.19
  17. Wells A. Messersmith · 2 shared papers, 2021 · strength 0.19
  18. Zeljka Jutric · 2 shared papers, 2016–2020 · strength 0.14
  19. Ronald Wolf · 2 shared papers, 2016–2018 · strength 0.14
  20. Eric Tran · 1 shared paper, 2021 · strength 0.10
  21. Martin D. McCarter · 1 shared paper, 2021 · strength 0.09
  22. Sara Zakem · 1 shared paper, 2021 · strength 0.09
  23. David Lagares · 1 shared paper, 2021 · strength 0.09
  24. Todd S. Crocenzi · 1 shared paper, 2016 · strength 0.05
  25. Chet W. Hammill · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.